The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.815 · Cited by 792
Self-citationVALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Walsky, R. L., & Obach, R. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.647 · Cited by 507
Self-citationGorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Scordo, M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129321 · Cited by 344
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates
Kenworthy, Bloomer, Clarke, & Houston (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00073.x · Cited by 336
Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S., Poulsen, H. E., & Brøsen, K. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050163 · Cited by 321
Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
Thummel, K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00039-2 · Cited by 318
Mayhew, B. S., Jones, D. R., & Hall, S. D. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15182-3 · Cited by 293
Tucker, G. T., Houston, J. B., & Huang, S. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.temp.1441.x · Cited by 284
Self-citationROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION
Isoherranen, N., Kunze, K. L., Allen, K. E., Nelson, W. L., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000315 · Cited by 276 · cited 1×
“In addition, for itraconazole, an unusual phenomenon, the inhibition of CYP3A caused by metabolites prior to release, has been reported to confound the prediction of the magnitude of drug interactions caused by this drug (Isoherannen et al., 2004).”
BackgroundBertelsen, K. M., Venkatakrishnan, K., von Moltke, L. L., Obach, R. S., & Greenblatt, D. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.289 · Cited by 276
Self-citationDatabase analyses for the prediction of in vivo drug–drug interactions from in vitro data
Ito, K., Brown, H. S., & Houston, J. B. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02041.x · Cited by 272
Self-citationKoudriakova, T., Iatsimirskaia, E., Utkin, I., Gangl, E. T., Vouros, P., Storozhuk, E., Orza, D., Marinina, J., & Gerber, N. (1998) · PubMed · Cited by 259
The influence of quinolone derivatives on theophylline clearance.
Wijnands, W. J. A., Vree, T. B., & Herwaarden, C. V. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb02957.x · Cited by 253
Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors
Ernest, C. S., Hall, S. D., & Jones, D. R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075416 · Cited by 246
Rostami-Hodjegan, A., & Tucker, G. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.10.002 · Cited by 239
Olkkola, K. T., Ahonen, J., & Neuvonen, P. J. (1996) · Anesthesia & Analgesia · doi:10.1097/00000539-199603000-00015 · Cited by 224
THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS*
WRIGHTON, S. A., SCHUETZ, E. G., THUMMEL, K. E., SHEN, D. D., KORZEKWA, K. R., & WATKINS, P. B. (2000) · Drug Metabolism Reviews · doi:10.1081/dmr-100102338 · Cited by 213
The Stereoselective Interaction of Warfarin and Metronidazole in Man
O'Reilly, R. A. (1976) · New England Journal of Medicine · doi:10.1056/nejm197608122950702 · Cited by 209
Kinetics of drug-drug interactions
Rowland, M., & Matin, S. B. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059791 · Cited by 208
PREDICTION OF CYTOCHROME P450 3A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES
Wang, Y.-H., Jones, D. R., & Hall, S. D. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.2.259 · Cited by 200
Br�sen, K., Hansen, J. G., Nielsen, K. K., Sindrup, S. H., & Gram, L. F. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316471 · Cited by 193
Benet, L., Cummins, C., & Wu, C. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489389 · Cited by 188
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
Backman, J., Olkkola, K., Aranko, K., Himberg, J., & Neuvonen, P. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04266.x · Cited by 184
Kirchheiner, J., Bauer, S., Meineke, I., Rohde, W., Prang, V., Meisel, C., Roots, I., & Brockmöller, J. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00004 · Cited by 169
Pharmacokinetics of the Newer Benzodiazepines
Garzone, P. D., & Kroboth, P. D. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916060-00002 · Cited by 164
Ito, K., Ogihara, K., Kanamitsu, S.-I., & Itoh, T. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.945 · Cited by 163
Drug Metabolism and Drug Interactions: Application and Clinical Value of In Vitro Models
Venkatakrishnan, K., von Moltke, L., Obach, R., & Greenblatt, D. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489361 · Cited by 162
Self-citationCYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions
Galetin, A., Ito, K., Hallifax, D., & Houston, J. B. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.082826 · Cited by 158
Self-citationMoltke, L. L., Greenblatt, D. J., Cotreau-Bibbo, M. M., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38622-2 · Cited by 156
Kalgutkar, A. S. S., Vaz, A. D. N., Lame, M. E., Henne, K. R., Soglia, J. R., Zhao, S. X., Abramov, Y. A., Lombardo, F., Collin, C., Hendsch, Z. S., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001735 · Cited by 155
Tucker, G. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116891 · Cited by 154
Jones, D. R., Gorski, J. C., Hamman, M. A., Mayhew, B. S., Rider, S., & Hall, S. D. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35013-x · Cited by 152
Centorrino, F., Baldessarini, R. J., Frankenburg, F. R., Kando, J. C., Volpicelli, S. A., & Flood, J. G. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.6.820 · Cited by 151
Ito, K., Hallifax, D., Obach, R. S., & Houston, J. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.003715 · Cited by 149
Self-citationPlasma buspirone concentrations are greatly increased by erythromycin and itraconazole*
Kivistö, K. T., Lamberg, T. S., Kantola, T., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90038-2 · Cited by 147
Hsyu, P., Schultz-Smith, M. D., Lillibridge, J. H., Lewis, R. H., & Kerr, B. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3445-3450.2001 · Cited by 144
Hamelin, B. A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.106464 · Cited by 141
Margolis, J. M., & Obach, R. S. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.606 · Cited by 138
Self-citationÁrnadóttir, M., Eriksson, L.-O., Thysell, H., & Karkas, J. D. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000187521 · Cited by 137
Effect of Fluvoxamine on the Pharmacokinetics of Imipramine and Desipramine in Healthy Subjects
Spina, E., Pollicino, A., Avenoso, A., Campo, G. M., Perucca, E., & Caputi, A. P. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199306000-00011 · Cited by 132
Kanamitsu, S.-I., Ito, K., & Sugiyama, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007509324428 · Cited by 130
Alderman, J. A., Preskorn, S., Greenblatt, D. J., Harrison, W. M., Penenberg, D. N., Allison, J., & Chung, M. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00008 · Cited by 121
Furuta, T., Ohashi, K., Kobayashi, K., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70034-2 · Cited by 121
Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam
Palkama, V. J., Ahonen, J., Neuvonen, P. J., & Olkkola, K. T. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70051-2 · Cited by 120
Venkatakrishnan, K., & Obach, R. S. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004077 · Cited by 120
Self-citationKharasch, E. D., Russell, M., Mautz, D. S., Thummel, K. E., Kunze, K. L., Bowdle, A. T., & Cox, K. (1997) · Anesthesiology · doi:10.1097/00000542-199707000-00006 · Cited by 114
Effects of cimetidine and ranitidine on hepatic drug metabolism
Breen, K. J., Bury, R. W., Desmond, P. V., Mashford, M. L., Morphett, B. J., Westwood, B. E., & Shaw, R. G. (1982) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1982.36 · Cited by 112
Hatorp, V., Hansen, K. T., & Thomsen, M. S. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003253704 · Cited by 110
Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir
Greenblatt, D. J., Moltke, L. L., Harmatz, J. S., Durol, A. L. B., Daily, J. P., Graf, J. A., Mertzanis, P., Hoffman, J. L., & Shader, R. I. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200006010-00007 · Cited by 103
Influence of methylxanthine‐containing foods on theophylline metabolism and kinetics
Monks, T. J., Caldwell, J., & Smith, R. L. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1979264513 · Cited by 103
Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb00001.x · Cited by 102
Prueksaritanont, T., Ma, B., Tang, C., Meng, Y., Assang, C., Lü, P., Reider, P. J., Lin, J. H., & Baillie, T. A. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00903.x · Cited by 102
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes
Yasui‐Furukori, N., Takahata, T., Nakagami, T., Yoshiya, G., Inoue, Y., Kaneko, S., & Tateishi, T. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02047.x · Cited by 90
McConn, D. J., Lin, Y. S., Allen, K. E., Kunze, K. L., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.10.1083 · Cited by 87
Progress Towards Prediction of Human Pharmacokinetic Parameters from In Vitro Technologies
Houston, J. B., & Galetin, A. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120026870 · Cited by 86
Self-citationGram, L. F., Hansen, M. G. J., Sindrup, S. H., Brøsen, K., Poulsen, J. H., Aaes‐Jørgensen, T., & Overø, K. F. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199302000-00003 · Cited by 84
Spina, E., Avenosoa, A., Facciolá, G., Fabrazzo, M., Monteleone, P., Maj, M., Perucca, E., & Caputi, A. R. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199805000-00009 · Cited by 84
Böttiger, Y., Tybring, G., Götharson, E., & Bertilsson, L. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90116-8 · Cited by 84
Effect of erythromycin on theophylline kinetics
Prince, R. A., Wing, D. S., Weinberger, M. M., Hendeles, L., & Riegelman, S. (1981) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(81)90196-2 · Cited by 83
Cytochrome P450 3A expression and activity in the human small intestine
YANG, J., Tucker, G. T., & Rostami‐Hodjegan, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.001 · Cited by 80
Inhibition‐Based Metabolic Drug–Drug Interactions: Predictions from In Vitro Data
Yao, C., & Levy, R. H. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10179 · Cited by 74
Komatsu, K., Ito, K., Nakajima, Y., Kanamitsu, S.-I., Imaoka, S., Funae, Y., Green, C. E., Tyson, C. A., Shimada, N., & Sugiyama, Y. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15066-0 · Cited by 74
Bannister, S. J., Houser, V. P., Hulse, J. D., et al. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb07186.x · Cited by 70
Huang, S. M., Lesko, L. J., & Williams, R. L. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922011764 · Cited by 67
Soons, P. A., van den Berg, G., Danhof, M., van Brummelen, P., Jansen, J. B. �. �., Lamers, C. B. H. W., & Breimer, D. D. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf00266355 · Cited by 66
Toon, S., Hopkins, K., Garstang, F. M., & Rowland, M. (1987) · European Journal of Clinical Pharmacology · doi:10.1007/bf00542190 · Cited by 66
The effect of sertraline on the pharmacokinetics of desipramine and imipramine
Kurtz, D. L., Bergstrom, R. F., Goldberg, M. J., & Cerimele, B. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90062-x · Cited by 64
Mephenytoin hydroxylation deficiency: Kinetics after repeated doses
Kupfer, A., Desmond, P. V., Patwardhan, R. V., et al. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.5 · Cited by 61
Madani, S., Barilla, D., Cramer, J. A., Wang, Y., & Paul, C. F. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002762491299 · Cited by 60
Zimmermann, T., Yeates, R. A., Laufen, H., et al. (1996) · PubMed · Cited by 55
Effect of erythromycin in patients receiving long-term warfarin therapy.
Weibert, R. T., Lorentz, S., Townsend, R. J., Cook, C. E., Klauber, M. R., & Jagger, P. I. (1989) · PubMed · Cited by 52
Frye, R. F., & Branch, R. A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01522.x · Cited by 49
Priskorn, M., Sidhu, J. S., Larsen, F., Davis, J. D., Khan, A. Z., & Rolan, P. E. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00628.x · Cited by 49
Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide
Madsen, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.112689 · Cited by 48
Interaction of propoxyphene with diazepam, alprazolam and lorazepam.
Abernethy, D., Greenblatt, D. J., Morse, D. S., & Shader, R. I. (1985) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1985.tb02612.x · Cited by 47
Kharasch, E. D., Hankins, D. C., Jubert, C., Thummel, K. E., & Taraday, J. K. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15310-x · Cited by 46
Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism
Tateishi, T., Kumai, T., Watanabe, M., Nakura, H., Tanaka, M., & Kobayashi, S. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00914.x · Cited by 44
Griseofulvin and Fluvoxamine Interactions with the Metabolism of Theophylline
Rasmussen, B. B., Jeppesen, U., Gaist, D., & Brøsen, K. (1997) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199702000-00010 · Cited by 44
Propranolol interactions with diazepam, lorazepam, and alprazolam
Ochs, H. R., Greenblatt, D. J., & Verburg-Ochs, B. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.203 · Cited by 42
The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone
Lamberg, T. S., Kivistö, K. T., Laitila, J., et al. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050548 · Cited by 41
Tucker, G., Houston, J. B., & Huang, S. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00148-8 · Cited by 41
Self-citationEffect of phenyramidol and bishydroxycoumarin on the metabolism of tolbutamide in human subjects
Solomon, H. M., & Schrogie, J. J. (1967) · Metabolism · doi:10.1016/0026-0495(67)90097-2 · Cited by 40
Ranitidine influences the uptake of oral midazolam.
Elwood, R. J., Hildebrand, P. J., Dundee, J., & Collier, P. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb01559.x · Cited by 39
Effect of Terbinafine on Theophylline Pharmacokinetics in Healthy Volunteers
Trépanier, E. F., Nafziger, A. N., & Amsden, G. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.695 · Cited by 37
Interaction between tolbutamide and ketoconazole in healthy subjects.
Krishnaiah, Y. S. R., Satyanarayana, S., & Visweswaram, D. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04262.x · Cited by 36
Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects
Spina, E., Avenoso, A., Campo, G. M., Scordo, M. G., Caputi, A. P., & Perucca, E. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00539.x · Cited by 36
Svendsen, T. L., Kristensen, M., Hansen, J. M., & Skovsted, L. (1976) · European Journal of Clinical Pharmacology · doi:10.1007/bf00606562 · Cited by 35
Effects of metronidazole on midazolam metabolism in vitro and in vivo
Wang, J.-S., Backman, J. T., Kivistö, K. T., & Neuvonen, P. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000201 · Cited by 34
Pharmacokinetic interaction between proton pump inhibitors and roxithromycin in volunteers
Kees, Holstege, Ittner, et al. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00731.x · Cited by 33
Neal, J. M., Kunze, K. L., Levy, R. H., O’Reilly, R. A., & Trager, W. F. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.8.1043 · Cited by 33
Pharmacokinetic interaction of disulfiram and antidepressants
Ciraulo, D. A., Barnhill, J. W., & Boxenbaum, H. G. (1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.11.1373 · Cited by 33
Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics
Loi, C., Day, J. D., Jue, S. G., Bush, E. D., Costello, P., Dewey, L. V., & Vestal, R. E. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.61 · Cited by 32
Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data.
Shou, M. (2005) · PubMed · Cited by 32
Pourbaix, S., Desager, J., Hulhoven, R., et al. (1985) · PubMed · Cited by 31
Tremaine, L. M., Wilner, K. D., & Preskorn, S. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00005 · Cited by 31
Self-citationThe effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam
Donnell, C. G. M., Harte, S. E., O'Driscoll, J. G., OLOUGHLIN, C., Pelt, F. D. V., & Shorten, G. D. (2003) · Anaesthesia · doi:10.1046/j.1365-2044.2003.03339.x · Cited by 31
Paulsen, O., Nilsson, L. ‐., Saint–Salvi, B., et al. (1988) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1988.tb00943.x · Cited by 29
Gillum, J. G., Israel, D. S., Scott, R. B., et al. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.7.1715 · Cited by 29
Hall, J., Naranjo, C. A., Sproule, B. A., et al. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085407.08426.e1 · Cited by 27
Gidal, B. E., Sorkness, C. A., McGill, K. A., Larson, R. A., & Levine, R. R. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199502000-00006 · Cited by 26
Effect of fluconazole on theophylline disposition in humans
Konishi, H., MORITA, K., & Yamaji, A. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00194397 · Cited by 25
Salazar, D. E., Dockens, R. C., Milbrath, R. L., Raymond, R. H., Fulmor, I. E., Chaikin, P., & Uderman, H. D. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04114.x · Cited by 25
Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent
He, N., Huang, S., Zhu, R., Tan, Z., Liu, J., Zhu, B. Y., & Zhou, H. (2003) · Xenobiotica · doi:10.1080/0049825021000023996 · Cited by 24
Calvo, G., García‐Gea, C., Luque, A., Morte, A., Dal‐Ré, R., & Barbanoj, M. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000125689.05091.c6 · Cited by 23
Guerret, M., Francheteau, P., & Hubert, M. (1997) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03753.x · Cited by 21
Physiological Approaches to the Prediction of Drug-Drug Interactions in Study Populations
Chien, J. Y., Mohutsky, M. A., & Wrighton, S. A. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489307 · Cited by 21
A Study of Pharmacokinetic Interaction Between Buspirone and Alprazolam at Steady State
Buch, A., Harken, D. R. V., SEIDEHAMEL, R. J., et al. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb01947.x · Cited by 19
Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration
Raaska, K., Raitasuo, V., & Neuvonen, P. J. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0523-9 · Cited by 16
Lack of inhibitory effect of metronidazole on theophylline disposition in healthy subjects.
Adebayo, G. I., & Mabadeje, A. F. B. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03146.x · Cited by 13
Dockens, R. C., Rapoport, D. M., Roberts, D., Greene, D. S., & Barbhaiya, R. H. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05806.x · Cited by 13
Diltiazem Treatment Impairs Theophylline Elimination in Patients with Bronchospastic Airway Disease
Soto, J., Sacristán, J. A., & Alsar, M. J. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199402000-00008 · Cited by 10
Effect of Clarithromycin on the Pharmacokinetics of Tolbutamide
Jayasagar, G., A.A. Dixit, V. Kishan, et al. (2000) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2000.16.3.207 · Cited by 8
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationPhysiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Obach, R. S., Walsky, R. L., & Venkatakrishnan, K. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012633 · Cited by 460
Self-citation
Metadata
- Authors
- Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B., & Tremaine, L. M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 316
- Issue
- 1
- Pages
- 336-348
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2096483010
- Cited by
- 433
- References
- 114
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.